Condensed Consolidated Statements of Earnings (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Net revenues	$ 12,310	$ 12,225
Cost of products sold	4,094	3,986
Selling, general and administrative	3,315	3,039
Research and development	1,939	2,292
Acquired IPR&D and milestones	164	150
Other operating income	0	(10)
Total operating costs and expenses	9,512	9,457
Operating earnings	2,798	2,768
Interest expense, net	453	454
Net foreign exchange loss	4	35
Other expense, net	586	1,804
Earnings before income tax expense	1,755	475
Income tax expense	383	234
Net earnings	1,372	241
Net earnings attributable to noncontrolling interest	3	2
Net earnings attributable to AbbVie Inc.	$ 1,369	$ 239
Per share data
Basic earnings per share (in dollars per share)	$ 0.77	$ 0.13
Diluted earnings per share (in dollars per share)	$ 0.77	$ 0.13
Weighted-average basic shares outstanding (in shares)	1,769	1,770
Weighted-average diluted shares outstanding (in shares)	1,773	1,776